Btk Antibody (DFW): sc-81736
- Btk Antibody (DFW) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against a recombinant protein corresponding to amino acids 212-275 (SH3 domain) of Btk of human origin
- recommended for detection of Btk of mouse, rat and human origin by WB, IP and FCM
- See Btk (E-9): sc-28387 for Btk antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Btk Antibody (DFW) for WB applications. These reagents are now offered in bundles with Btk Antibody (DFW) (see ordering information below).
QUICK LINKS
SEE ALSO...
Btk Antibody (DFW) is a mouse monoclonal IgG1 antibody that detects Btk in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). Btk, or Bruton′s tyrosine kinase, plays a crucial role in B cell development and signaling, making Btk essential for the proper functioning of the immune system. Mutations in the Btk gene can lead to X-linked agammaglobulinemia, a condition characterized by a significant reduction in B cells and immunoglobulins, which leaves affected individuals vulnerable to infections. Btk is primarily located in the cytoplasm and becomes activated upon B cell receptor engagement, leading to downstream signaling that promotes cell survival and proliferation. Understanding Btk function and regulation is vital for developing targeted therapies for immunodeficiencies and related disorders. Anti-Btk antibody (DFW) provides a reliable tool for researchers studying B cell biology and the mechanisms underlying immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Btk Antibody (DFW) References:
- From identification of the BTK kinase to effective management of leukemia. | Smith, CI. 2017. Oncogene. 36: 2045-2053. PMID: 27669440
- Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. | Ran, F., et al. 2022. Eur J Med Chem. 229: 114009. PMID: 34839996
- Novel BTK Inhibitors for Treating Autoimmune Disorders and Cancer. | Sabnis, RW. 2022. ACS Med Chem Lett. 13: 759-760. PMID: 35586429
- The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System. | Cao, T., et al. 2022. J Inflamm Res. 15: 6427-6438. PMID: 36452053
- Addressing cardiovascular complications of BTK inhibitors. | Moslehi, J. 2023. Clin Adv Hematol Oncol. 21: 94-96. PMID: 36780475
- Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases. | Lin, P., et al. 2023. Curr Top Med Chem. 23: 2609-2620. PMID: 37861005
- Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states. | Lin, DY., et al. 2024. Elife. 12: PMID: 38189455
- Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas. | Song, PR., et al. 2024. Acta Pharmacol Sin. 45: 2163-2173. PMID: 38834683
- Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis. | Turner, TJ., et al. 2024. Drugs R D. 24: 263-274. PMID: 38965189
- The potential of Bruton's tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease. | Tseng, H. and Murrell, DF. 2024. Expert Opin Pharmacother. 25: 1657-1665. PMID: 39158385
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Btk Antibody (DFW) | sc-81736 | 200 µg/ml | $322.00 | |||
Btk Antibody (DFW): m-IgG Fc BP-HRP Bundle | sc-539661 | 200 µg Ab; 10 µg BP | $361.00 | |||
Btk Antibody (DFW): m-IgG1 BP-HRP Bundle | sc-541642 | 200 µg Ab; 20 µg BP | $361.00 |